Review Form 1.6

Journal Name:	**Journal of Pharmaceutical Research International**
Manuscript Number:	**Ms_JPRI_93400**
Title of the Manuscript:	**Challenges in the research and development of Orphan drugs: A comprehensive review**
Type of the Article	

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty'**, provided the manuscript is scientifically robust and technically sound.
To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(https://www.journaljpri.com/index.php/JPRI/editorial-policy)

PART 1: Review Comments

	Reviewer's comment	**Author's comment** *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)*
Compulsory REVISION comments	This is a comprehensive review about the challenges of developing orphan drugs. Throughout the document it is shown information about the genetic tests, table 1 (correlation of regulation of rare diseases and orphan drugs between different countries), table 2 (list of FDA approved orphan drugs), …but with no reference of the source used to collect the information or a description of the methodology used to have the information. I miss many references to explain the points shown in the review: all the legislation that support the fact that there are incentives of governments to the development of orphan drugs, the list of complications of developing orphan drugs in section 2, the trials in table 3. In the abstract, the authors introduce the topic including Australia in the review, but the only reference to the situation in this country is in table 2, third column.	
Minor REVISION comments	I strongly suggest revising the statements about that rare diseases affect mostly to children. This idea is widely repeated in the same and different sections: Introduction, second sentence, first point and second paragraph. Point four of the review: *Most of the rare diseases, nearly 80% are of genetic origin and usually affect children.* Also, the idea that a rare disease affect small population of patients is conversely explained in the second section. I recommend to better explain *while others affect a huge population.* Reference 2 in the text does not allude to the US rare condition definition but Indian.	
Optional/General comments	I strongly recommend to change the brand name of the drugs in table 2 by the name of the molecule that is easily recognized in scientific literature.	

PART 2:

	Reviewer's comment	**Author's comment** *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)*
Are there ethical issues in this manuscript?	*(If yes, Kindly please write down the ethical issues here in details)*	

Reviewer Details:

Name:	**Mercedes Núñez**
Department, University & Country	**Spain**